Estimating the U.S. prevalence of chronic obstructive pulmonary disease using pre- and post-bronchodilator spirometry: the National Health and Nutrition Examination Survey (NHANES) 2007-2010

Timothy Tilert, Charles Dillon, Ryne Paulose-Ram, Eva Hnizdo, Brent Doney, Timothy Tilert, Charles Dillon, Ryne Paulose-Ram, Eva Hnizdo, Brent Doney

Abstract

Background: During 2007-2010, the National Health and Nutrition Examination Survey (NHANES) conducted a spirometry component which obtained pre-bronchodilator pulmonary lung function data on a nationally representative sample of US adults aged 6-79 years and post-bronchodilator pulmonary lung function data for the subset of adults with airflow limitation. The goals of this study were to 1) compute prevalence estimates of chronic obstructive pulmonary disease (COPD) using pre-bronchodilator and post-bronchodilator spirometry measurements and fixed ratio and lower limit of normal (LLN) diagnostic criteria and 2) examine the potential impact of nonresponse on the estimates.

Methods: This analysis was limited to those aged 40-79 years who were eligible for NHANES pre-bronchodilator spirometry (n=7,104). Examinees with likely airflow limitation were further eligible for post-bronchodilator testing (n=1,110). Persons were classified as having COPD based on FEV1/FVC < 70% (fixed ratio) or FEV1/FVC < lower limit of normal (LLN) based on person's age, sex, height, and race/ethnicity. Those without spirometry but self-reporting both daytime supplemental oxygen therapy plus emphysema and/or current chronic bronchitis were also classified as having COPD. The final analytic samples for pre-bronchodilator and post-bronchodilator analyses were 77.1% (n=5,477) and 50.8% (n=564) of those eligible, respectively. To account for non-response, NHANES examination weights were adjusted to the eligible pre-bronchodilator and post-bronchodilator subpopulations.

Results: In 2007-2010, using the fixed ratio criterion and pre-bronchodilator test results, COPD prevalence was 20.9% (SE 1.1) among US adults aged 40-79 years. Applying the same criterion to post-bronchodilator test results, prevalence was 14.0% (SE 1.0). Using the LLN criterion and pre-bronchodilator test results, the COPD prevalence was 15.4% (SE 0.8), while applying the same criterion to post-bronchodilator test results, prevalence was 10.2% (SE 0.8).

Conclusions: The overall COPD prevalence among US adults aged 40-79 years varied from 10.2% to 20.9% based on whether pre- or post-bronchodilator values were used and which diagnostic criterion (fixed ratio or LLN) was applied. The overall prevalence decreased by approximately 33% when airflow limitation was based on post-bronchodilator as compared to pre-bronchodilator spirometry, regardless of which diagnostic criterion was used.

Figures

Figure 1
Figure 1
Flow diagram of the study population.

References

    1. Global Initiative for Chronic Obstructive Lung Disease (GOLD) Global Strategy for the Diagnosis, Management and Prevention of COPD. 2013. .
    1. Barnes TA, Fromer L. Spirometry use: detection of chronic obstructive pulmonary disease in the primary care setting. Clin Interv Aging. 2011;6:47–52.
    1. American Thoracic Society - European Respiratory Society. Standards for the Diagnosis and Management of Patients with COPD. .
    1. CDC. Chronic obstructive pulmonary disease among adults - United States, 2011. MMWR MMWR. 2012;61:938–943.
    1. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, Coates A, van der Grinten CP, Gustafsson P, Hankinson J, Jensen R, Johnson DC, MacIntyre N, McKay R, Miller MR, Navajas D, Pedersen OF, Wanger J. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948–968. doi: 10.1183/09031936.05.00035205.
    1. Steinacher R, Parissis JT, Strohmer B, Eichinger J, Rottlaender D, Hoppe UC, ltenberger J. Comparison between ATS/ERS age-and gender-adjusted criteria and GOLD criteria for the detection of irreversible airway obstruction in chronic heart failure. Clin Res Cardiol. 2012;101(8):637–645. doi: 10.1007/s00392-012-0438-0.
    1. Calverley PMA. The GOLD Classification Has Advanced Understanding of COPD. Am J Respir Crit Care Med. 2004;170(3):211–212. doi: 10.1164/rccm.2405008.
    1. Hardie JA, Buist AS, Vollmer WM, Ellingsen I, Bakke PS, Morkve O. Risk of over-diagnosis of COPD in asymptomatic elderly never-smokers. Eur Respir J. 2002;20(5):1117–1122. doi: 10.1183/09031936.02.00023202.
    1. Celli BR, Halbert RJ, Isonaka S, Schau B. Population impact of different definitions of airway obstruction. Eur Respir J. 2003;22(2):268–273. doi: 10.1183/09031936.03.00075102.
    1. Bakke PS, Ronmark E, Eagan TM, Pistelli F, Annesi-Maesano I, Maly M, Meren M, Zielinski J, Viegi G, Lundback B. Recommendations for epidemiological studies on COPD. Eur Respir J. 2012;39(5):1278–1279. doi: 10.1183/09031936.00011712.
    1. National Center for Health Statistics. National Health and Nutrition Examination Survey. .
    1. Zipf G, Chiappa M, Porter K, Ostchega Y, Lewis B, Dostal J. The National Health and Nutrition Examination Survey: Plan and Operations, 1999–2010. Vital Health Stat. 2013;1(56):10–22.
    1. Hankinson JL, Odencrantz JR, Fedan KB. Spirometric reference values from a sample of the general U.S. population. Am J Respir Crit Care Med. 1999;159(1):179–87. doi: 10.1164/ajrccm.159.1.9712108.
    1. Miller MR, Hankinson J, Brusasco V, Burgos F, Casaburi R, Coates A, Crapo R, Enright P, van der Grinten CP, Gustafsson P, Jensen R, Johnson DC, MacIntyre N, McKay R, Navajas D, Pedersen OF, Pellegrino R, Viegi G, Wanger J. Standardisation of spirometry. Eur Respir J. 2005;26(2):319–338. doi: 10.1183/09031936.05.00034805.
    1. NHANES. Respiratory Health - Bronchodilator Procedures Manual. .
    1. Hankinson JL, Kawut SM, Shahar E, Smith LJ, Stukovsky KH, Barr RG. Performance of American Thoracic Society-Recommended Spirometry Reference Values in a Multiethnic Sample of AdultsThe Multi-Ethnic Study of Atherosclerosis (MESA) Lung Study. CHEST. 2010;137(1):138–145. doi: 10.1378/chest.09-0919.
    1. National Center for Health Statistics. NHANES Analytic and Reporting Guidelines. .
    1. Wun LM, Ezzati-Rice TM, Diaz-Tena N, Greenblatt J. On modelling response propensity for dwelling unit (DU) level non-response adjustment in the Medical Expenditure Panel Survey (MEPS) Stat Med. 2007;26(8):1875–84. doi: 10.1002/sim.2809.
    1. Kalton G, Flores-Cervantes I. Weighting methods. Journal of Official Statistics-Stockholm. 2003;19(2):81–98.
    1. Potter F, Grau E, Williams S, Diaz-Tena N, Carlson BL. An application of propensity modeling: Comparing unweighted and weighted logistic regression models for nonresponse adjustments. Proceedings of the Survey Research Methods Section. American Statistical Association. .
    1. Graham JW, Olchowski AE, Gilreath TD. How many imputations are really needed? - Some practical clarifications of multiple imputation theory. Prev Sci. 2007;8(3):206–213. doi: 10.1007/s11121-007-0070-9.
    1. Menezes AM, Pérez-Padilla R, Hallal PC, Jardim JR, Muiño A, López MV, Valdivia G, Pertuze J, De Oca MM, Tálamo C. Worldwide burden of COPD in high- and low-income countries. Part II. Burden of chronic obstructive lung disease in Latin America: the PLATINO study. Int J Tuberc Lung Dis. 2008;12(7):709–12.
    1. Johannessen A, Omenaas ER, Bakke PS, Gulsvik A. Implications of reversibility testing on prevalence and risk factors for chronic obstructive pulmonary disease: a community study. Thorax. 2005;60(10):842–7. doi: 10.1136/thx.2005.043943.
    1. Pérez-Padilla R, Hallal PC, Vázquez-García JC, Muiño A, Máquez M, López MV, De Oca MM, Tálamo C, Valdivia G, Pertuzé J, Jardim J, Menezes AM. Impact of bronchodilator use on the prevalence of COPD in population-based samples. COPD. 2007;4(2):113–20. doi: 10.1080/15412550701341012.
    1. Shirtcliffe P, Weatherall M, Marsh S, Travers J, Hansell A, McNaughton A, Aldington S, Muellerova H, Beasley R. COPD prevalence in a random population survey: a matter of definition. Eur Respir J. 2007;30(2):232–9. doi: 10.1183/09031936.00157906.
    1. Vollmer WM, Enrigh PL, Buist AS, Gislason P, Burney P, Gulsvik A, Kocabas A. Comparison of spirometry criteria for the diagnosis of COPD: results from the BOLD study. Eur Respir J. 2009;34(3):588–597. doi: 10.1183/09031936.00164608.
    1. Cerveri I, Corsico AG, Accordini S, Niniano R, Ansaldo E, Anto JM, Kunzli N, Janson C, Sunyer J, Jarvis D, Svanes C, Gislason T, Heinrich J, Schouten JP, Wjst M, Burney P, De Marco R. Underestimation of airflow obstruction among young adults using FEV(1)/FVC < 70% as a fixed cut-off: a longitudinal evaluation of clinical and functional outcomes. Thorax. 2008;63(12):1040–1045. doi: 10.1136/thx.2008.095554.
    1. Menezes AM, Pérez-Padilla R, Jardim JB, Muiño A, López MV, Valdivia G, De Oca MM, Tálamo C, Hallal PC, Victora CG. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): a prevalence study. LANCET. 2005;366(9500):1875–1881. doi: 10.1016/S0140-6736(05)67632-5.
    1. Mannino DM, Buist AS, Petty TL, Enright PL, Redd SC. Lung function and mortality in the United States: data from the First National Health and Nutrition Examination Survey follow up study. Thorax. 2003;58:388–393. doi: 10.1136/thorax.58.5.388.
    1. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and meta-analysis. Eur Respir J. 2006;28(3):523–32. doi: 10.1183/09031936.06.00124605.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다